The European Patent Office (EPO) has published patent application EP2026030684A1, titled 'EXOSOME POPULATIONS COMPRISING GLYCO-MODIFIED RNAS AND METHODS OF USE THEREOF'. This publication, dated March 18, 2026, details specific exosome populations and the use of glyco-modified RNAs within them, along with associated methods of use. The application lists several International Patent Classification (IPC) codes, including A61K (Preparations for medical, dental or toilet purposes), C12N (Microorganisms or enzymes; Compositions thereof), and A61P (Specific therapeutic activity of chemical compounds or medicinal preparations).

This patent publication is primarily of interest to entities involved in pharmaceutical research and development, biotechnology, and intellectual property management within the European Union. While it does not impose direct compliance obligations, it signifies potential future developments in therapeutic technologies. Companies operating in the biotech and pharmaceutical sectors should monitor this patent's progress and consider its implications for their own research and development pipelines, particularly concerning exosome-based therapies and RNA modifications.